Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.

Rodriguez-Garcia A, Watanabe K, Guedan S.

Methods Mol Biol. 2020;2086:251-271. doi: 10.1007/978-1-0716-0146-4_19.

PMID:
31707682
2.

Analysis of CAR-Mediated Tonic Signaling.

Calderon H, Mamonkin M, Guedan S.

Methods Mol Biol. 2020;2086:223-236. doi: 10.1007/978-1-0716-0146-4_17.

PMID:
31707680
3.

Immobilizing A Moving Target: CAR T Cells Hit CD22.

Guedan S, Delgado J.

Clin Cancer Res. 2019 Sep 1;25(17):5188-5190. doi: 10.1158/1078-0432.CCR-19-1649. Epub 2019 Jul 2.

PMID:
31266831
4.

Engineering and Design of Chimeric Antigen Receptors.

Guedan S, Calderon H, Posey AD Jr, Maus MV.

Mol Ther Methods Clin Dev. 2018 Dec 31;12:145-156. doi: 10.1016/j.omtm.2018.12.009. eCollection 2019 Mar 15. Review.

5.

Emerging Cellular Therapies for Cancer.

Guedan S, Ruella M, June CH.

Annu Rev Immunol. 2019 Apr 26;37:145-171. doi: 10.1146/annurev-immunol-042718-041407. Epub 2018 Dec 10.

PMID:
30526160
6.

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.

Guedan S, Alemany R.

Front Immunol. 2018 Oct 23;9:2460. doi: 10.3389/fimmu.2018.02460. eCollection 2018. Review.

7.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.

JCI Insight. 2018 Apr 5;3(7). pii: 99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5.

8.

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.

Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S.

Cancer Immunol Res. 2018 May;6(5):605-616. doi: 10.1158/2326-6066.CIR-17-0314. Epub 2018 Mar 27.

9.

Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A.

JCI Insight. 2018 Feb 22;3(4). pii: 94952. doi: 10.1172/jci.insight.94952. eCollection 2018 Feb 22.

10.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH.

JCI Insight. 2018 Jan 11;3(1). pii: 96976. doi: 10.1172/jci.insight.96976. eCollection 2018 Jan 11.

11.

Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.

Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R.

Cancer Res. 2017 Apr 15;77(8):2052-2063. doi: 10.1158/0008-5472.CAN-16-1708. Epub 2017 Jan 31.

12.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Kawalekar OU, O' Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH.

Immunity. 2016 Mar 15;44(3):712. doi: 10.1016/j.immuni.2016.02.023. Epub 2016 Mar 15. No abstract available.

13.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH.

Immunity. 2016 Feb 16;44(2):380-90. doi: 10.1016/j.immuni.2016.01.021. Erratum in: Immunity. 2016 Mar 15;44(3):712. Snyder, Nathaniel [corrected to Snyder, Nathaniel W]; Blair, Ian [corrected to Blair, Ian A]. Erratum in: Immunity. 2016 Mar 15;44(3):712.

14.

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH.

Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19.

15.

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH.

Blood. 2014 Aug 14;124(7):1070-80. doi: 10.1182/blood-2013-10-535245. Epub 2014 Jul 1.

16.

GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.

Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R, Mercade E, Cascallo M, Alemany R.

Gene Ther. 2012 Nov;19(11):1048-57. doi: 10.1038/gt.2011.184. Epub 2011 Nov 24.

PMID:
22113313
17.

Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.

Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F, Cascallo M, Alemany R.

Mol Ther. 2010 Nov;18(11):1960-71. doi: 10.1038/mt.2010.173. Epub 2010 Aug 31.

18.

Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.

Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R.

Mol Ther. 2010 Jul;18(7):1275-83. doi: 10.1038/mt.2010.79. Epub 2010 May 4.

19.

Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses.

Gros A, Puig C, Guedan S, Rojas JJ, Alemany R, Cascallo M.

Mol Ther. 2010 May;18(5):903-11. doi: 10.1038/mt.2010.22. Epub 2010 Feb 23.

20.

A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.

Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, Alemany R.

Gene Ther. 2009 Dec;16(12):1441-51. doi: 10.1038/gt.2009.103.

PMID:
19710704
21.

Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency.

Gros A, Martínez-Quintanilla J, Puig C, Guedan S, Molleví DG, Alemany R, Cascallo M.

Cancer Res. 2008 Nov 1;68(21):8928-37. doi: 10.1158/0008-5472.CAN-08-1145.

22.

Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.

Guedan S, Gros A, Cascallo M, Vile R, Mercade E, Alemany R.

Gene Ther. 2008 Sep;15(17):1240-5. doi: 10.1038/gt.2008.94. Epub 2008 May 29.

Supplemental Content

Loading ...
Support Center